Akeso, Inc. (HK:9926) has released an update.
Akeso, Inc. has announced that its Phase III clinical trial results for ivonescimab, a first-in-class PD-1/VEGF bi-specific immuno-therapy drug for advanced lung cancer, will be presented at the 2024 World Conference on Lung Cancer. The drug, which has shown superior efficacy to pembrolizumab in a head-to-head setting, has also been submitted for supplemental New Drug Application in China. Ivonescimab has already been approved in China for a different indication and is currently undergoing multiple clinical trials for various cancers.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.
